Final Answer:
The nurse would anticipate vitamin K deficiency due to cholestyramine therapy for type II hyperlipoproteinemia.
Step-by-step explanation:
Cholestyramine is a bile acid sequestrant commonly used to treat type II hyperlipoproteinemia, a condition characterized by elevated levels of low-density lipoprotein (LDL) cholesterol. While cholestyramine effectively lowers cholesterol levels by binding bile acids in the intestines, this binding process may also interfere with the absorption of fat-soluble vitamins, including vitamin K.
Vitamin K plays a crucial role in blood clotting, and its deficiency can lead to impaired coagulation. As cholestyramine binds to bile acids, it forms complexes that are excreted in the feces, reducing the absorption of fat-soluble compounds. Since vitamin K is essential for synthesizing clotting factors in the liver, a deficiency can result in an increased risk of bleeding disorders. The nurse should monitor the patient for signs of vitamin K deficiency, such as easy bruising or prolonged bleeding, and consider appropriate supplementation if necessary.
It's important for healthcare providers to weigh the benefits of cholesterol management against potential nutrient deficiencies when prescribing medications like cholestyramine. Patient education on maintaining a balanced diet and, if needed, supplementation of fat-soluble vitamins like K during therapy is crucial to mitigate the risk of deficiencies and ensure overall well-being. Regular monitoring and collaboration between healthcare professionals help strike a balance between therapeutic efficacy and potential side effects, promoting the best possible patient outcomes.